Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), responsible for ensheathing axons with a multilamellar myelin sheath that enables rapid saltatory conduction of action potentials. Their dysfunction and death are central features of multiple neurodegenerative diseases, making them critical targets for therapeutic intervention.
| Property |
Value |
| Category |
Glial Cells |
| Location |
White and gray matter throughout CNS |
| Cell Type |
Post-mitotic oligodendrocytes and OPCs |
| Function |
Myelin production, axonal support, metabolic support |
- Cell body: Small (10-15 μm diameter), dark nucleus
- Processes: Multiple (up to 15) primary processes
- Myelination capacity: Each oligodendrocyte can myelify up to 60 axons
- Myelin sheath: Multi-lamellar structure (10-20 layers)
- Proliferative capacity: Divide throughout life
- Distribution: 5-10% of total CNS cells
- Differentiation potential: Can become mature oligodendrocytes
- Marker proteins: NG2 proteoglycan, PDGFRA, CSPG4
- Proteolipid protein (PLP): 50% of myelin protein
- Myelin basic protein (MBP): 30% of myelin protein
- Myelin oligodendrocyte glycoprotein (MOG): Surface marker
- CNP (2',3'-Cyclic Nucleotide 3'-Phosphodiesterase): Cytoplasmic protein
- OPCs proliferate and migrate to target regions
- Process extension and axon selection
- Membrane wrapping and compaction
- Myelin sheath maturation
- Larger diameter axons preferentially myelinated
- Nodes of Ranvier strategically positioned
- Internode length correlates with axon properties
- Lactate shuttling: Provide metabolic substrates to axons
- Mitochondrial transfer: Support axonal energy demands
- Glutamate recycling: Clear extracellular glutamate
- Trophic support: Secretion of neurotrophic factors
- Iron homeostasis: Regulation of iron metabolism
- Calcium regulation: Buffering extracellular calcium
- Demyelination: Primary pathological feature
- OPC dysfunction: Failure of remyelination
- Axonal degeneration: Secondary to demyelination
- Chronic lesions: Glial scarring, failed repair
- White matter abnormalities: Detected by MRI
- Oligodendrocyte loss: Observed in postmortem tissue
- Myelin breakdown: Early event in disease progression
- Tau pathology: Affects oligodendrocytes directly
- Oligodendrocyte vulnerability: Reduced numbers in substantia nigra
- Myelin abnormalities: Observed in prodromal stages
- α-Synuclein pathology: Can affect oligodendrocytes
- Metabolic dysfunction: Energy production deficits
- Oligodendrocyte degeneration: Pre-motor neuron loss
- Impaired glutamate transport: Affects excitotoxicity
- Energy metabolism: Mitochondrial dysfunction
- OPC proliferation: Reactive changes observed
- White matter loss: Progressive atrophy
- Oligodendrocyte pathology: Impaired function
- Myelin gene expression: Downregulated
- Dysregulated lipid metabolism: Affects myelin maintenance
- Apoptosis: Caspase-dependent cell death
- Necrosis: Energy failure-induced
- Autophagy: Dysregulated autophagic flux
- Oxidative stress: ROS accumulation
- Cytokine release: IL-1β, TNF-α, IL-6
- Microglial activation: Cross-talk with oligodendrocytes
- Complement attack: MAC deposition on myelin
- Matrix metalloproteinases: Myelin degradation
- AMPA/Kainate receptor overactivation: Calcium influx
- Glutamate transporter dysfunction: Impaired clearance
- Metabolic failure: Energy depletion
- Mitochondrial dysfunction: ATP shortage
- OPC recruitment: CXCR4 agonists, LINGO-1 antagonists
- Differentiation factors: Thyroid hormone, neurotrophins
- Block inhibitors: Anti-NgR antibodies, anti-RhoA
- Antioxidants: N-acetylcysteine, CoQ10
- Anti-inflammatory agents: Minocycline, salicylates
- Metabolic support: Ketogenic diet, glucose optimization
- PLP gene delivery: For demyelinating diseases
- CNP overexpression: Promotes process extension
- MBP restoration: Critical for myelination
- OPC transplantation: Human ESC-derived OPCs
- Oligodendrocyte transplantation: Direct cell therapy
- iPSC-derived cells: Patient-specific therapy
- MRI: White matter hyperintensities, T2 lesions
- DTI: Diffusion tensor imaging for tract integrity
- MRS: Metabolite changes in normal-appearing white matter
- PET: Myelin-specific tracers
- MBP: Myelin breakdown product
- NFL: Neurofilament light chain
- GFAP: Astrocyte activation
- CHIT1: Microglial activation marker
- NfL: Neurofilament light chain
- GFAP: Glial fibrillary acidic protein
- ** Tau**: Axonal damage marker
- Primary cultures: Rodent and human oligodendrocytes
- OPC lines: Immortalized cell lines
- Co-cultures: Oligodendrocyte-neuron interactions
- Cuprizone model: Toxic demyelination
- Lysolecithin model: Focal demyelination
- Transgenic models: Genetic demyelinating diseases
- EAE model: Autoimmune demyelination
- Electron microscopy: Ultra-structural analysis
- Confocal microscopy: Protein localization
- Live imaging: Calcium dynamics, process movement
Oligodendrocytes are essential for CNS function, providing not only electrical insulation through myelination but also critical metabolic and trophic support to axons. Their dysfunction contributes to the pathogenesis of numerous neurodegenerative diseases, including MS, AD, PD, ALS, and HD. Understanding oligodendrocyte biology offers promising avenues for developing therapies that promote remyelination, protect existing myelin, and support axonal health.
- Bradl & Lassmann, Oligodendrocytes in Disease (2020)
- Simons & Nave, Oligodendrocyte Function (2022)
- Feigin et al., White Matter in Parkinson's Disease (2021)
- Boehm et al., Oligodendrocyte Death in ALS (2019)
- Nave & Werner, Myelin and Neurodegeneration (2021)
- Chrzanowski et al., Oligodendrocyte Precursor Cells (2020)